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Infection of different human epithelial cell lines with human respiratory syncytial virus (HRSV) revealed significant differ-
ences in the electrophoretic mobility of the viral attachment glycoprotein (G). Cell-type specific differences in G protein
glycosylation were observed with certain lectins and sugar-specific reagents. Furthermore, substantial changes in the
reactivity of the G glycoprotein with anti-G monoclonal antibodies were associated to the infected cell type. Strain-specific
epitopes—present in a limited number of HRSV isolates of the same antigenic group—were particularly susceptible to cell-
type-specific modifications of the mature G protein. Some of these epitopes, which were either exposed in the unglycosylated
precursor or reproduced with synthetic peptides, were nonetheless masked in the mature G protein expressed in certain
cell lines. Antigenic and electrophoretic mobility changes of the G glycoprotein were reverted in extracts of HEp-2 cells
infected with HRSV grown in other cell types, indicating that phenotypic traits rather than selection of variants were
associated to the above stated changes. These results highlight the importance of cell-type-specific modifications for HRSV
G glycoprotein antigenicity and raise questions about the actual antigenic structure of this molecule when HRSV replicates
in the respiratory tract. q 1996 Academic Press, Inc.
INTRODUCTION (Johnson et al., 1987). Flanking this region, there are two
protein segments which are highly divergent among
Human respiratory syncytial virus (HRSV) is the single
HRSV isolates (Cane et al., 1991; Sullender et al., 1991;
most important cause of severe lower respiratory tract
Garcı´a et al., 1994) and with a high content of serines
infections in very young children (review by McIntosh
and threonines, potential sites for O-glycosylation. Theand Chanock, 1990). The virus is a member of the Pneu-
G protein precursor of 32 kDa is cotranslationally modi-movirus genus of the Paramixoviridae family. The G gly-
fied by the addition of high-mannose N-linked sugars tocoprotein—the attachment protein—is responsible for
form an intermediate of 45 kDa (Wertz et al., 1989; Collinsvirus binding to the cell surface receptor (Levine et al.,
and Mottet, 1992). This step is followed by conversion of1987). Despite playing similar roles in the replicative cy-
the N-linked sugars to the complex type and addition ofcle, the G glycoprotein shares neither sequence nor
O-linked sugars to achieve the mature form of 80– 90structural features with the attachment protein (HN or
kDa [estimated by sodium dodecyl sulfate–polyacryl-H) of other paramyxoviruses. Instead, the high serine,
amide gel electrophoresis (SDS–PAGE)]. A soluble/se-threonine, and proline content of the G glycoprotein
creted form of the G protein (Gs) (Hendricks et al., 1988)(Wertz et al., 1985) resembles the amino acid composi-
is apparently generated by initiation of translation at antion of the mucins, a class of proteins produced and
alternative AUG triplet placed in the middle of the hy-secreted by epithelial cells (review by Apostolopoulos
drophobic domain (Roberts et al., 1994).and McKenzie, 1994).
Seroepidemiological data and immunization studiesThe G molecule is a type II glycoprotein with a single
done with laboratory animals indicate that protectionhydrophobic domain between residues 38 and 66 which
against HRSV is mediated by neutralizing antibodies thatserves as both membrane anchor and signal sequence.
recognize both the G glycoprotein and the other surfaceIn the middle of the ectodomain there is a short protein
glycoprotein, the fusion protein (F) (Olmsted et al., 1986;segment (amino acids 164 –176) and four cysteines (resi-
Stott et al., 1987; Walsh et al., 1987). HRSV isolates havedues 173, 176, 182, and 186) which are conserved in all
been subdivided into two antigenic groups (A and B)HRSV isolates. This region is slightly hydrophobic and
based on their reactivity with panels of monoclonal anti-has been proposed as the putative receptor binding site
bodies (MAbs). The G glycoprotein is the HRSV gene
product with the highest degree of genetic and antigenic1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 34-1-509 7918. diversity among viral isolates. Monoclonal anti-G anti-
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bodies distinguish three types of epitopes in the G mole- Lens culinaris (LCA, specific for a-mannosyl residues),
cule: (i) conserved epitopes which are shared by all viral Arachis hipogaea (PNA, galactoseb(1-3)-N-acetyl galac-
isolates, (ii) group-specific antibodies which are present tosamine), Ricinus communis (RCL, b-D-galactose), and
in all viruses from the same antigenic group, and (iii) Sambucus nigra (SNA, a(2-6)-linked sialic acid). In addi-
strain-specific or variable epitopes present only in certain tion, the following carbohydrate specific MAbs were
strains of the same antigenic group (Anderson et al., used: T218 and T174 (anti-Lewis b and -Lewis a, respec-
1985; Garcı´a-Barreno et al., 1989). The capacity of HRSV tively; Sakamoto et al., 1986), FH4 (anti-Lewis x*; Fukushi
to reinfect the same individual has been related to et al., 1984), 77/180 and 57/27 (anti-Lewis y and -Lewis
changes in the antigenic properties of the virus, particu- a, respectively; de Bolo´s et al., 1995), and AM-3 (anti-
larly in the G glycoprotein (Mufson et al., 1987; Waris, sialyl Lewis x; Hanski et al., 1990).
1991), suggesting that immune selection of new variants,
as indicated from evolutionary studies of HRSV (Garcı´a
Preparation of cell extracts and viruseset al., 1994; Cane and Pringle, 1995), may contribute to
the epidemiology of HRSV infections. Consequently, a
Subconfluent cell monolayers were infected with eitherdetailed knowledge of the G protein antigenic structure
Long or Mon/3/88 strains of HRSV (1–5 PFU/cell). Whenshould help to understand both the basis of antibody
an extensive cytopathic effect was evident (48–72 hrprotection and the mechanisms for evading a preexisting
after infection, depending on the cell line), the cells wereimmune response.
scrapped off with a rubber policeman and pelleted byPrevious studies indicated the relevance of carbohy-
low-speed centrifugation (3000 g, 5 min). Virus was sedi-drates for both infectivity and antigenicity of the G glycopro-
mented from culture supernatants by centrifugation attein (Lambert, 1988). Specially, most anti-G MAbs that rec-
125,000 g for 90 min at 47 and resuspended in a smallognized strain-specific epitopes did not react in Western
volume of phosphate-buffered saline (PBS). Cell pelletsblots with the unglycosylated precursor of the G protein
were resuspended in extraction buffer (10 mM Tris–HCl,but reacted with the O-glycosylated and the mature forms
pH 7.6, 5 mM EDTA, 140 mM NaCl, 1% Triton X-100,of the G molecule (Palomo et al., 1991). Since the pattern
and 1% sodium deoxycholate) by strong vortexing. Cellof protein glycosylation is cell type specific—depending
extracts were clarified by centrifugation at 10,000 g forupon the spectrum of glycosyl transferases and glycosi-
5 min and kept at 0207 until used.dases present within the cell—we tested whether infection
of different cell types with HRSV would lead to changes
in G protein antigenicity. We focused our study in cells of
Western immunoblotepithelial origin because they are the host cell type for
HRSV in a natural infection. At the same time, these studies
Proteins from cell extracts were separated by SDS–could be the basis for an experimental model to test glyco-
PAGE and electrotransferred to Immobilon paper (Milli-sylation changes in mucin-like glycoproteins associated
pore) by the method of Towbin et al. (1979). The paperwith tumor development (Apostolopoulos and McKenzie,
was saturated with 10% nonfat dry milk in PBS, incubated1994; Lesuffleur et al., 1994).
with the antibodies indicated in the figure legends for 1 hr
at room temperature, and developed with biotinylated anti-
MATERIALS AND METHODS
mouse Ig, streptavidin–peroxidase, and 4-chloro-1-naphtol
as recommended by the manufacturer (Amersham).Cells and viruses
To test G protein changes in glycosylation, cell extracts
The Long (isolated in Baltimore, MD, in 1956) and Mon/ were first immunoprecipiated with biotinylated lectins
3/88 (isolated in Montevideo, Uruguay, in 1988) strains and streptavidin–agarose (Sigma). Proteins were then
of HRSV were plaque purified twice and grown routinely dissociated in SDS–sample buffer, resolved by SDS–
in HEp-2 cells as described (Garcı´a-Barreno et al., 1988). PAGE, and electrotransferred to Hybond PVDF mem-
The cell lines used in this study are listed in Table 1. branes (Amersham). Membranes were then incubated
They were grown in Dulbecco’s modified Eagle’s medium with the group-specific MAb 021/19G and developed with
supplemented with 10% fetal calf serum and antibiotics. peroxidase-labeled anti-mouse Ig and chemoluminis-
cence with ECL (Amersham). Alternatively, the G protein
Immunological and carbohydrate reagents
was first immunoprecipitated with MAb 021/19G in com-
bination with rabbit anti-mouse Ig and formalin-fixedAnti-G MAbs raised against the Long strain have been
Staphylococcus aureus (GIBCO) and resolved by SDS–described (Garcı´a-Barreno et al., 1989). Monoclonal anti-
PAGE. After electrotransfer to Hybond PVDF membranes,G antibodies raised against the Mon/3/88 strain, labeled
G protein was detected with mouse MAbs reactive withwith the prefix 021, will be described elsewhere (Martı´-
either carbohydrate epitopes or HRSV G protein, biotinyl-nez et al., manuscript in preparation). The biotinylated
lectins (Vector Laboratories) used in this study were from ated anti-mouse Ig, streptavidin–peroxidase, and ECL.
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TABLE 1
Characteristics of Human Cell Lines Used in This Study
Name Origin Differentiated properties References
HEp-2 Epidermoid carcinoma of larynx Epithelial-like morphology Moore et al. (1955)
HT-29 Colon carcinoma Epithelial; undifferentiated, form multilayers and do not Fogh and Trempe (1975)
secrete mucins
M6 HT-29 cells adapted to grow in Epithelial; form monolayers of goblet cells and secrete Lesuffleur et al. (1990)
1006 methotrexate mucins
M3 HT-29 cells adapted to grow in Epithelial; form monolayers of absorptive cells, do not Lesuffleur et al. (1991)
1003 M methotrexate secrete mucins
Caco-2 Colon carcinoma Epithelial, enterocyte-like Pinto et al. (1983)
SKLC.1 Lung carcinoma Epithelial-like morphology Feickert et al. (1990)
SKLC.13 Lung carcinoma Epithelial-like morphology Feickert et al. (1990)
KNS.62 Lung carcinoma Epithelial-like morphology Feickert et al. (1990)
A-549 Lung carcinoma Epithelial-like morphology Giard et al. (1973)
L-132 Embrionic lung Fibroblast-like morphology Davis (1961)
RESULTS mobility of the G polypeptide were observed among dif-
ferent cell types. The lines derived from colon carcino-
Identification of the G protein accumulated in extracts mas (HT29, M6, M3, and Caco-2) generated G molecules
of different cell lines infected with HRSV with lower mobility than HEp-2, which is the standard
cell line for growing HRSV (Fig. 1A). HT-29 cells deriveInfection of the cell lines listed in Table 1 with HRSV
from a colon carcinoma, form multilayers, and less thanled to productive infection in all cases. Cytopathic effects,
5% of the cells secrete mucins (Lesuffleur et al., 1990,as evidenced by cell death, were observed 48 to 72 hr
1991; Egea et al., 1993) (Table 1). In contrast, M6 cells,postinfection depending on the cell type. Similar amounts
derived from HT-29 by adaptation to grow in the presenceof virus were recovered from supernatants of infected
of 1006 M methotrexate, form a homogeneous monolayercells, as determined by limiting dilution titration in HEp-
of mucus-secreting cells. M3 cells, derived from M6 by2 cell monolayers (not shown). Extracts of HRSV (Long
adaptation to grow in 1003 M methotrexate, form a mono-strain)-infected cells and pelleted virus were prepared
layer but do not secrete mucins. The mobility of the Gand tested for the presence of G glycoprotein by Western
protein produced in Caco-2 cells, a line derived from ablot with the group-specific MAb 021/19G (Fig. 1). A wide
colon carcinoma with enterocytic properties and whichband ranging from 80 to 120 kDa was detected in all
cell extracts but clear differences in the electrophoretic does not secrete mucins, was similar to that of the G
FIG. 1. Electrophoretic mobility of the G glycoprotein from different cell types. The cell lines indicated at the top of A and C were infected with
the Long strain of HRSV. Extracts were made and analyzed by Western blot with antibody 021/19G, as indicated under Materials and Methods.
Viruses pelleted from supernatants of infected cells indicated at the top of B were analyzed by Western blot with the same antibody. The positions
of molecular weight makers (in kilodaltons) and the G protein are shown to the left and the right, respectively.
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protein expressed in M6 cells. Therefore, no correlation
was found between G protein mobility and the mucus-
secreting phenotype. Similar electrophoretic mobility
changes were observed in the G protein present in vi-
ruses pelleted from supernatants of colon carcinoma
cells (Fig. 1B), although in this case the G bands were
wider than in the case of cell extracts.
Cell lines derived from lung carcinomas generated G
proteins with either different band patterns—as in
SKLC.1 and SKLC.13 where discrete bands were ob-
served—or band mobility (KNS.62) compared to that of
HEp-2 cells. L-132 cells, derived from normal lung epithe-
lium and displaying fibroblast-like morphology, gener-
ated a G protein with mobility and band shape similar to
those of HEp-2 cells (Fig. 1C), as did the lung carcinoma-
derived A-459 cell line (not shown).
Reactivity of the G protein with sugar-specific lectins
and antibodies
Differences in electrophoretic mobility, as described
in the previous section, could result from changes in the
glycosylation of the G molecule. It is known that different
cells or cell types may differ in the set of glycosyltransfer-
ases and/or glycosidases that determine the final carbo- FIG. 2. Western blot of G glycoprotein from infected cell extracts
hydrate composition of their glycoconjugates. To exam- with sugar-specific reagents. Biotinylated lectins from Lens culinaris
ine the glycosylation of the G protein present in extracts (LCA), Arachis hypogaea (PNA), Ricinus communis (RCL), and Sambu-
cus nigra (SNA) or antibody T218 were used to isolate glycoproteinsof infected HEp-2, HT-29, M6, M3, and Caco-2 cells, gly-
from the Long-infected cell extracts, as indicated under Materials andcoproteins were purified with biotinylated lectins and
Methods. The glycoproteins were separated by SDS–PAGE, electro-
streptavidin–agarose, resolved by SDS–PAGE, electro- transferred to PVDF membranes, and blotted with the anti-G specific
transferred to membranes, and probed with MAb 021/ antibody 021/19G. To estimate the amount of G protein, cell extracts
19G as indicated under Materials and Methods (Fig. 2). were immunoprecipitated with antibody 021/19G and blotted with the
same antibody. The specificity of each carbohydrate-specific reagentTo account for differences in the efficiency of the infec-
is indicated below its name.tions, the levels of G protein detected in whole cell ex-
tracts by Western blotting with antibody 021/19G were
taken as reference. Lectin LCA (specific for a-mannose) Host-cell-dependent changes of G protein reactivity
(Fig. 2) and antibodies recognizing sialyl-Lewis a (57/27, with monoclonal antibodies
not shown) were reactive to a similar extent with all cell
extracts tested. Antibodies recognizing Lewis a (T174), We have reported that certain G protein epitopes are
not present in the unglycosylated precursor (Palomo etsialyl-Lewis x (AM-3), or Lewis y (77/180) were unreactive
with all cell extracts analyzed (not shown). As shown in al., 1991), emphasizing the relevance of carbohydrate side
chains for G protein antigenicity. To test whether differ-Fig. 2, PNA (specific for Galb1,3GalNAc), RCL (specific
for Gal), SNA (specific for NeuAca2,6), and antibody T218 ences in mobility and glycosylation could influence the
antigenicity of the G molecule, infected cell extracts, stan-(specific for Lewis b) showed cell-type-specific differ-
ences in their reactivity with the G molecule. Interest- dardized for the same amount of G with antibody 021/19G
(see Fig. 1), were tested by Western blot with anti-G MAbsingly, HT-29 and its two derivatives, M6 and M3, showed
differences in the intensity of the G protein band detected raised against the Long strain (Garcı´a-Barreno et al., 1989).
The examples shown in Fig. 3 illustrate the results ob-with PNA and RCL, suggesting that variations in the gly-
cosylation machinery were selected while growing HT- tained. Some antibodies, such as 63G, did not react with
the G protein from HT-29 and related cell lines (M6 and29 in the presence of methotrexate. The G protein pro-
duced in HEp-2 and Caco-2 cells did not react with anti- M3); however, other antibodies, such as 26G, reacted to
a different extent with the G protein of the three cell lines,body T218 recognizing Lewis b, an epitope determined
by a complex structure in which Gal, GlcNAc, and Fuc in line with the differences in mobility and glycosylation
observed in Figs. 1 and 2. Some antibodies, such as 59Gare involved. The sialic acid-specific epitope recognized
by SNA was present in the G protein from HEp-2 cells and 62G, reacted with the G protein from most cell lines
(except SKLC.13), whereas others (e.g., 8G) were restrictedbut not from the other cell types.
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FIG. 3. Western blot of infected cell extracts with different anti-G antibodies raised against the Long strain. The cell lines indicated at the top of
each lane were infected with the Long strain of HRSV. Extracts were made and analyzed by Western blot with the antibodies indicated at the
bottom of each panel. Symbols, as in Fig. 1. Gin , maturation intermediates of the G glycoprotein.
to the G protein from HEp-2 cells. Antibody 25G was reac- represented in either the unglycosylated G protein pre-
cursor (25G, 63G, 26G, 74G) (Palomo et al., 1991) ortive with N-glycosylated G intermediates (Gin), even in cell
lines, such as Caco-2, in which the mature G protein was synthetic peptides (63G) (Garcı´a-Barreno et al., 1992)
were masked, nonetheless, in the mature G moleculeunreactive with that antibody, indicating that cell-depen-
dent O-glycosylation may account for masking of epitope from some cell types.
To extend our studies to another HRSV strain in which25G in the G molecule.
A summary of the results obtained with the panel of strain-specific, group-specific, and conserved epitopes
have been located in the G protein primary structureanti-G antibodies raised against the Long strain is shown
in Fig. 4A. These antibodies recognize strain-specific epi- (Martı´nez et al., manuscript in preparation), all cell lines
were infected with Mon/3/88 virus and extracts testedtopes that were classified previously in antigenic areas
by competition for simultaneous binding to antigen by Western blot with the antibodies indicated in Fig. 5.
As in the case of the Long strain, the strain-specific epi-(Garcı´a-Barreno et al., 1989). The amino acids essential
for epitope integrity have been located within the C-termi- topes of Mon/3/88 G protein have been mapped in the
C-terminal third of the primary structure, except epitopenal third of the G polypeptide by analysis of antibody
escape mutants (Garcı´a-Barreno et al., 1990; Rueda et 021/5G that was located in the variable region preceding
the cysteine cluster (Fig. 4B). All strain-specific epitopesal., 1991, 1995) and synthetic peptides (Garcı´a-Barreno
et al., 1992) (Fig. 4B). In general, the reactivity profile of were masked in certain cell lines and one of them (021/
7G) was exposed only in the G protein from HEp-2-in-antibodies with the G protein from different cell extracts
reflected their classification in antigenic areas. For in- fected cells. In contrast, the group-specific and con-
served epitopes, located in the central region of the Gstance, epitopes 26G and 28G of area VII could not be
distinguished from others of the same area except by protein ectodomain (Rueda et al., 1994, 1995; Martı´nez
et al., manuscript in preparation) (Fig. 5B), were ex-virus-binding inhibition with anti-idiotypic antibodies
(Rueda et al., 1995). Accordingly, antibodies 26G and 28G pressed in the G molecule of all infected cell extracts.
As it happened with some Long-specific antibodies, theshowed different reactivity profiles in Fig. 4A than other
antibodies included in area VII. Certain linear epitopes Mon/3/88 strain-specific antibodies 021/5G and 021/9G,
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FIG. 4. Reactivity of infected cell extracts with anti-G antibodies raised against the Long strain. The cell types indicated to the left of A were
infected with the Long strain of HRSV and the reactivity of the G protein with the panel of antibodies shown at the top was tested by Western blot,
as illustrated in Fig. 3. (j) Strong reactivity, (‰) weak reactivity, and (h) no reactivity, compared with the G protein from HEp-2 cells. B shows a
scheme of the Long strain G protein primary structure, denoting the transmembrane region (Ò), cysteine residues (l), potential sites for N (.)-
and O-glycosylation ( ), and the location of amino acid residues essential for integrity of the indicated antigenic areas.
which recognized the unglycosylated G protein precursor test whether these changes resulted from virus selection
in the course of infection, supernatants obtained from(not shown, Martı´nez et al., manuscript in preparation),
failed to react with the mature G glycoprotein from certain infected HEp-2, M3, and SKLC.1 cells were used to infect
new HEp-2 cultures. The reactivity of extracts and mobil-cell extracts.
The results presented in Figs. 4 and 5 were obtained ity of G protein prepared from these cells were identical
irrespective of the origin of the supernatant used for in-by Western blot. Reactivity of the G protein from different
cell extracts with certain MAbs was also tested by dot- fection (Figs. 6B and 6D).
blot or ELISA. The results obtained in the different assays
were always comparable. Due to the fact that individual DISCUSSION
MAbs raised against the G protein reduced virus titer
The results presented here illustrate changes in bothonly marginally (Garcı´a-Barreno et al., 1989), the effect
electrophoretic mobility and antigenicity of the G glyco-of antibodies upon neutralization of HRSV grown in differ-
protein upon infection of different epithelial cell lines withent cell types could not be examined.
HRSV. These changes were associated with cell-specific
glycosylation differences of the G molecule, as demon-Reversion of mobility and antigenic changes upon
strated with certain lectins and carbohydrate-specific an-passage of HRSV in HEp-2 cells
tibodies (Fig. 2). Phenotypic rather than genotypic
changes were involved in the mobility and antigenic dif-The G protein antigenic changes described in previous
sections were observed in cells infected with plaque- ferences of the G glycoprotein, as indicated by the rever-
sion of those traits when Mon/3/88 virus from M3 orpurified HRSV grown in HEp-2 cells. This is shown again
in Figs. 6A and 6C, where the G protein from M3 and SKLC.1 cell supernatants was used to infect HEp-2 cells.
This situation is in contrast to that described for influenzaSKLC.1 cells infected with HEp-2-grown Mon/3/88 virus
did not react with antibodies 021/16G and 021/7G. To virus, in which passage of the virus in the allantoic cavity
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FIG. 5. Reactivity of infected cell extracts with anti-G antibodies raised against the Mon/3/88 strain. Cells were infected with Mon/3/88 virus and
tested for antibody reactivity as indicated in Fig. 4. The epitopes of antibodies shown at the top of A have been classified as strain-specific (SS),
group-specific (GS), and conserved (C), according to their distribution in a panel of HRSV isolates (Martı´nez et al., unpublished). Epitope location,
as deduced from escape mutant analysis, is indicated in B, above the scheme of the G protein primary structure of Mon/3/88 virus. Symbols, as
in Fig. 4.
of embryonated eggs selects a subpopulation of virus closer to the in vivo situation than established cell lines.
The limited data obtained until now—due to scarce avail-with antigenic changes in virus hemagglutinin (Schild et
al., 1983). In that case, infection of MDCK cells with egg- ability of infected material—indicate that the G protein from
extracts of Long- or Mon/3/88-infected tracheal biopsiesgrown virus does not revert the antigenic properties of
influenza hemagglutinin. have the same electrophoretic mobility as that from infected
HEp-2 cells (not shown). Also, the electrophoretic mobilityThe above considerations raise questions about the ac-
tual antigenic structure of the G glycoprotein when HRSV of the G glycoprotein from Hep-2 and normal lung L-132-
infected cells is indistinguishable and only two epitopesreplicates in the respiratory tract. The experimental ap-
proach to solve this question is complicated by the extreme (8G and 021/7G) were missing in the last case (Figs. 4 and
5). In addition, the mobility and antigenic characteristics ofantigenic variation of HRSV isolates (Cane and Pringle,
1995; Garcı´a et al., 1994). Thus, analysis of antibody reactiv- the G protein from infected CV-1, Vero, and HeLa cells
resemble those found in extracts of infected HEp-2 cellsity of the G glycoprotein from nasopharyngeal specimens
with strain-specific MAbs directed against Long or Mon/3/ (not shown). Given these findings, we favor the idea that
the antigenic properties of the G glycoprotein from extracts88 would be inappropriate since the origin of the infectious
virus is unknown. In addition, population polymorphism in of HEp-2-infected cells are similar to those of the ‘‘natural’’
G protein found in the respiratory tract. However, furtherthe expression of certain carbohydrate epitopes, such as
the Lewis series (Lloyd and Old, 1989; Oriol, 1995), might experiments, perhaps in an animal model system, are
needed to clarify this situation.complicate the interpretation of antibody binding studies.
Only MAbs raised against the G glycoprotein of a virus Certain epitopes (25G, 63G, 26G, 74G, 021/5G, and
021/9G) which are exposed in the unglycosylated precur-isolate from which large amounts of the clinical specimen
were available would be useful for such studies. We have sor and in the mature G protein of HEp-2 cells were
masked in the mature G molecule from other cell types.attempted to circumvent this problem by infecting human
tracheal biopsies with HRSV, as an experimental system Presumably, the amino acid residues recognized by
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static process (Apostopoulos and McKenzie, 1994; Lesuf-
fleur et al., 1994). The use of HRSV G protein as a model
molecule may contribute to the elucidation of the molecu-
lar basis of such alterations.
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